TABLE 3.
The associations between the initiation of patient‐led basal insulin titration and pregnancy outcomes in linear regression models.
| Adjusted change associated with the intervention | ||
|---|---|---|
| Non‐insulin treated (comparator) group estimate (95% CI; p value) | Insulin treated group estimate (95% CI; p‐value) | |
| Increase in total daily insulin dose at 36 weeks gestation a (units per kg of pre‐pregnancy weight) | NA | 0.21 (0.03 to 0.38; p = 0.020) |
| Change in mean fasting glucose at 36 weeks gestation b (mmol/L) | −0.12 (−0.42 to 0.18; p = 0.408) | −0.54 (−1.07 to −0.02; p = 0.042) |
| Change in birthweight Z‐score c | −0.18 (−0.50 to 0.14; p = 0.270) | −0.61 (−1.01 to −0.22; p = 0.003) |
Abbreviation: NA, not applicable.
Complete data was available in the insulin‐treated group for 29 (97%) women before implementation and 41 (95%) after. Retained model adjustment variables: maternal age and maternal BMI.
Complete data was available in the non‐insulin‐treated group for 25 (36%) women before implementation and 24 (51%) after and the insulin‐treated group for 15 (46%) before and 18 (42%) after. Retained model adjustment variables: maternal ethnicity, and metformin use.
Complete data was available in the non‐insulin‐treated group for 75 (100%) women before implementation and 50 (100%) after and the insulin‐treated group for 30 (100%) before and 42 (98%) after. Retained adjustment variables: maternal age, maternal ethnicity, and metformin use.